Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorQuinaux, E-
dc.contributor.authorCORTINAS ABRAHANTES, Jose-
dc.contributor.authorTournigand, C-
dc.contributor.authorCervantes, A-
dc.contributor.authorFiger, A-
dc.contributor.authorAndré, Thierry-
dc.contributor.authorTabah-Fisch, I-
dc.contributor.authorDe Gramont, A-
dc.identifier.citationANNALS OF ONCOLOGY, 17. p. 115-115-
dc.description.abstractBackground: In the OPTIMOX1 study, previously untreated patients, (pts) with advanced CRC were randomized to either FOLFOX4 every 2 wks until progressio (arm A), or FOLFOX7 (arm B). There was no difference between arms in response rate, progression-free survival, and overall survival (OS)[Tournigand, JCO 2006;24:394]. The effect of oxaliplatin reintroduction on survival was inconclusive as a significant number of pts received oxaliplatin in both arms after being taken off the study. This retrospective analysis evaluated the effect of oxaliplatin reintroduction on OS. Methods: The % of pts with oxaliplatin reintroducion was calculated in each center regardless of treatment arm, number of pts, or whether reintroduction was per protocol. A Cox model was used to analyze impact of oxaliplatin reintroduction on survival, after adjustment for all baseline covariates, and using random effects to account for the fact that % pts with oxilaplatin reintroduction was estimated in each center. Centers were grouped into 4 reintroduction classes according to o% pts with oxaliplatin reintroduction (0, 1–20, 21–40, and >40). The hazard ratio (HR; adjusted for all baseline covariates) was calculated for each reintroduction class. Results: After adjustment for all other factors,% pts with oxaliplatin reintroduction had a highly significant impact on survival (p<0.001). Reintroduction class also had a significant impact on survival, after adjustment for all other factors (p=0.02; Table below). Median survival increased from 15 months in the 0% to 23 months in the >40% reintroduction class.-
dc.publisherOXFORD UNIV PRESS-
dc.titleAnalysis of oxaliplatin reintroduction in patients with advanced colorectal cancer (CRC) treated with FOLFOX4 or FOLFOX7 in the optimox study-
dc.typeJournal Contribution-
dc.description.notesInt Inst Drug Dev, Brussels, Belgium. Hasselt Univ, Ctr Stat, Hasselt, Belgium. Hop St Antoine, Med Oncol Serv, F-75571 Paris, France. Univ Hosp Valencia, Valencia, Spain. Elias Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel. Hop Tenon, Med Oncol Serv, F-75970 Paris, France. Sanofi Aventis, Paris, France.-
local.type.specifiedMeeting Abstract-
item.fulltextNo Fulltext-
item.accessRightsClosed Access-
item.fullcitationBUYSE, Marc; Quinaux, E; CORTINAS ABRAHANTES, Jose; Tournigand, C; Cervantes, A; Figer, A; André, Thierry; Tabah-Fisch, I & De Gramont, A (2006) Analysis of oxaliplatin reintroduction in patients with advanced colorectal cancer (CRC) treated with FOLFOX4 or FOLFOX7 in the optimox study. In: ANNALS OF ONCOLOGY, 17. p. 115-115.-
item.contributorFiger, A-
item.contributorTournigand, C-
item.contributorDe Gramont, A-
item.contributorCORTINAS ABRAHANTES, Jose-
item.contributorBUYSE, Marc-
item.contributorAndré, Thierry-
item.contributorCervantes, A-
item.contributorQuinaux, E-
item.contributorTabah-Fisch, I-
Appears in Collections:Research publications
Show simple item record

Page view(s)

checked on Jul 2, 2022

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.